Efficacy of intranasal administration of neostigmine in myasthenic patients

Angelo Sghirlanzoni, Davide Pareyson, Claudio Benvenuti, Giovanni Cei, Vittorio Cosi, Mariella Lombardi, Mariaflavia Nicora, Roberta Ricciardi, Ferdinando Cornelio

Research output: Contribution to journalArticle

Abstract

The efficacy of intranasally administered neostigmine was tested in 22 patients with generalized myasthenia gravis (MG). Topical therapy to the highly vascularized oropharynx proved to be quickly effective in 5-15 min both clinically and electrophysiologically. Twenty-eight MG patients were then recruited from different centres and their morning doses of oral pyridostigmine were substituted with intranasal neostigmine over a period of 2 or 3 weeks. Intranasal neostigmine proved to be equally efficacious in this regimen. No side-effect was noted even in 4 patients treated in this way for 1 year. Intranasal administration of anti-acetylcholinesterase may be very beneficial: (1) for patients with irregular absorption of oral doses; (2) early in the morning and every time a fast and temporary effect is needed; (3) in bulbar impairment and emergencies, in which a handy atomizer may be life-saving.

Original languageEnglish
Pages (from-to)165-169
Number of pages5
JournalJournal of Neurology
Volume239
Issue number3
DOIs
Publication statusPublished - Mar 1992

Fingerprint

Intranasal Administration
Neostigmine
Muscle Weakness
Myasthenia Gravis
Pyridostigmine Bromide
Oropharynx
Nebulizers and Vaporizers
Acetylcholinesterase
Emergencies
Therapeutics

Keywords

  • Autoimmunity
  • Cholinesterase inhibitors
  • Intranasal administration
  • Myasthenia gravis
  • Neostigmine

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Sghirlanzoni, A., Pareyson, D., Benvenuti, C., Cei, G., Cosi, V., Lombardi, M., ... Cornelio, F. (1992). Efficacy of intranasal administration of neostigmine in myasthenic patients. Journal of Neurology, 239(3), 165-169. https://doi.org/10.1007/BF00833919

Efficacy of intranasal administration of neostigmine in myasthenic patients. / Sghirlanzoni, Angelo; Pareyson, Davide; Benvenuti, Claudio; Cei, Giovanni; Cosi, Vittorio; Lombardi, Mariella; Nicora, Mariaflavia; Ricciardi, Roberta; Cornelio, Ferdinando.

In: Journal of Neurology, Vol. 239, No. 3, 03.1992, p. 165-169.

Research output: Contribution to journalArticle

Sghirlanzoni, A, Pareyson, D, Benvenuti, C, Cei, G, Cosi, V, Lombardi, M, Nicora, M, Ricciardi, R & Cornelio, F 1992, 'Efficacy of intranasal administration of neostigmine in myasthenic patients', Journal of Neurology, vol. 239, no. 3, pp. 165-169. https://doi.org/10.1007/BF00833919
Sghirlanzoni, Angelo ; Pareyson, Davide ; Benvenuti, Claudio ; Cei, Giovanni ; Cosi, Vittorio ; Lombardi, Mariella ; Nicora, Mariaflavia ; Ricciardi, Roberta ; Cornelio, Ferdinando. / Efficacy of intranasal administration of neostigmine in myasthenic patients. In: Journal of Neurology. 1992 ; Vol. 239, No. 3. pp. 165-169.
@article{755f50c8162c46788e1cdce33c5d5580,
title = "Efficacy of intranasal administration of neostigmine in myasthenic patients",
abstract = "The efficacy of intranasally administered neostigmine was tested in 22 patients with generalized myasthenia gravis (MG). Topical therapy to the highly vascularized oropharynx proved to be quickly effective in 5-15 min both clinically and electrophysiologically. Twenty-eight MG patients were then recruited from different centres and their morning doses of oral pyridostigmine were substituted with intranasal neostigmine over a period of 2 or 3 weeks. Intranasal neostigmine proved to be equally efficacious in this regimen. No side-effect was noted even in 4 patients treated in this way for 1 year. Intranasal administration of anti-acetylcholinesterase may be very beneficial: (1) for patients with irregular absorption of oral doses; (2) early in the morning and every time a fast and temporary effect is needed; (3) in bulbar impairment and emergencies, in which a handy atomizer may be life-saving.",
keywords = "Autoimmunity, Cholinesterase inhibitors, Intranasal administration, Myasthenia gravis, Neostigmine",
author = "Angelo Sghirlanzoni and Davide Pareyson and Claudio Benvenuti and Giovanni Cei and Vittorio Cosi and Mariella Lombardi and Mariaflavia Nicora and Roberta Ricciardi and Ferdinando Cornelio",
year = "1992",
month = "3",
doi = "10.1007/BF00833919",
language = "English",
volume = "239",
pages = "165--169",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "3",

}

TY - JOUR

T1 - Efficacy of intranasal administration of neostigmine in myasthenic patients

AU - Sghirlanzoni, Angelo

AU - Pareyson, Davide

AU - Benvenuti, Claudio

AU - Cei, Giovanni

AU - Cosi, Vittorio

AU - Lombardi, Mariella

AU - Nicora, Mariaflavia

AU - Ricciardi, Roberta

AU - Cornelio, Ferdinando

PY - 1992/3

Y1 - 1992/3

N2 - The efficacy of intranasally administered neostigmine was tested in 22 patients with generalized myasthenia gravis (MG). Topical therapy to the highly vascularized oropharynx proved to be quickly effective in 5-15 min both clinically and electrophysiologically. Twenty-eight MG patients were then recruited from different centres and their morning doses of oral pyridostigmine were substituted with intranasal neostigmine over a period of 2 or 3 weeks. Intranasal neostigmine proved to be equally efficacious in this regimen. No side-effect was noted even in 4 patients treated in this way for 1 year. Intranasal administration of anti-acetylcholinesterase may be very beneficial: (1) for patients with irregular absorption of oral doses; (2) early in the morning and every time a fast and temporary effect is needed; (3) in bulbar impairment and emergencies, in which a handy atomizer may be life-saving.

AB - The efficacy of intranasally administered neostigmine was tested in 22 patients with generalized myasthenia gravis (MG). Topical therapy to the highly vascularized oropharynx proved to be quickly effective in 5-15 min both clinically and electrophysiologically. Twenty-eight MG patients were then recruited from different centres and their morning doses of oral pyridostigmine were substituted with intranasal neostigmine over a period of 2 or 3 weeks. Intranasal neostigmine proved to be equally efficacious in this regimen. No side-effect was noted even in 4 patients treated in this way for 1 year. Intranasal administration of anti-acetylcholinesterase may be very beneficial: (1) for patients with irregular absorption of oral doses; (2) early in the morning and every time a fast and temporary effect is needed; (3) in bulbar impairment and emergencies, in which a handy atomizer may be life-saving.

KW - Autoimmunity

KW - Cholinesterase inhibitors

KW - Intranasal administration

KW - Myasthenia gravis

KW - Neostigmine

UR - http://www.scopus.com/inward/record.url?scp=0026576374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026576374&partnerID=8YFLogxK

U2 - 10.1007/BF00833919

DO - 10.1007/BF00833919

M3 - Article

C2 - 1573422

AN - SCOPUS:0026576374

VL - 239

SP - 165

EP - 169

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 3

ER -